Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelika Joos

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Therapeutic Innovation & Regulatory Science|January 3, 2024
Pediatric Market Access: A Qualitative StudyLieke Maas, Angelika Joos, Mickael Hiligsmann
International Journal of Technology Assessment in Health Care|September 25, 2018
EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTIONLina Balaisyte, Angelika Joos, Mickaël Hiligsmann
European Journal of Pediatrics|September 21, 2016
Moving toward a paradigm shift in the regulatory requirements for pediatric medicinesWilliam Wei Lim Chin, Angelika Joos
International Journal of Technology Assessment in Health Care|February 24, 2021
Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirementsHannah Sievers, Angelika Joos, Mickaël Hiligsmann
Frontiers in Medicine|September 21, 2023
What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvementsNevena Miletic, Sarah Adam, Jacqueline Acquah, et al.
Journal of Global Antimicrobial Resistance|February 16, 2022
Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and developmentLeon Rohde, Elias Mossialos, Charlotte Beaudart, et al.
Clinical Therapeutics|November 10, 2019
Orphan Medicines for Pediatric Use: A Focus on the European UnionWinona Rei Bolislis, Solange Corriol-Rohou, Claire Hill-Venning, et al.
Therapeutic Innovation & Regulatory Science|November 6, 2015
Partnering With Patients in the Development and Lifecycle of Medicines: A Call for ActionAnton Hoos, James Anderson, Marc Boutin, et al.
Clinical Pharmacology and Therapeutics|January 7, 2021
Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic ApproachesWinona Rei Bolislis, Gesine Bejeuhr, Fawzi Benzaghou, et al.
Journal of Pharmaceutical Sciences|September 12, 2014
Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control testJoerg H O Garbe, Susanne Ausborn, Claire Beggs, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Therapeutic Innovation & Regulatory Science|January 3, 2024
Pediatric Market Access: A Qualitative StudyLieke Maas, Angelika Joos, Mickael Hiligsmann
International Journal of Technology Assessment in Health Care|September 25, 2018
EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTIONLina Balaisyte, Angelika Joos, Mickaël Hiligsmann
European Journal of Pediatrics|September 21, 2016
Moving toward a paradigm shift in the regulatory requirements for pediatric medicinesWilliam Wei Lim Chin, Angelika Joos
International Journal of Technology Assessment in Health Care|February 24, 2021
Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirementsHannah Sievers, Angelika Joos, Mickaël Hiligsmann
Frontiers in Medicine|September 21, 2023
What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvementsNevena Miletic, Sarah Adam, Jacqueline Acquah, et al.
Journal of Global Antimicrobial Resistance|February 16, 2022
Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and developmentLeon Rohde, Elias Mossialos, Charlotte Beaudart, et al.
Clinical Therapeutics|November 10, 2019
Orphan Medicines for Pediatric Use: A Focus on the European UnionWinona Rei Bolislis, Solange Corriol-Rohou, Claire Hill-Venning, et al.
Therapeutic Innovation & Regulatory Science|November 6, 2015
Partnering With Patients in the Development and Lifecycle of Medicines: A Call for ActionAnton Hoos, James Anderson, Marc Boutin, et al.
Clinical Pharmacology and Therapeutics|January 7, 2021
Optimizing Pediatric Medicine Developments in the European Union Through Pragmatic ApproachesWinona Rei Bolislis, Gesine Bejeuhr, Fawzi Benzaghou, et al.
Journal of Pharmaceutical Sciences|September 12, 2014
Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control testJoerg H O Garbe, Susanne Ausborn, Claire Beggs, et al.
Pageof 2